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B) indicative for local antigenic stimulation (CD137). The 
same lesions also contained higher  CD8+ T-cell frequen-
cies expressing co-inhibitory (TIM3 and PD1) and co-stim-
ulatory (ICOS) T-cell receptors, yet no evidence for T-cell 
senescence (CD57) was observed. The oligoclonal T-cell 
receptor (TCR) repertoire, particularly among  CD8+ T 
cells, correlated between TCL generated from anatomically 
separated WML of the same MS patient, but not between 
paired NAWM and WML. Whereas no substantial T-cell 
reactivity was detected towards seven candidate human MS-
associated autoantigens (cMSAg), brisk  CD8+ T-cell reac-
tivity was detected in multiple WML-derived TCL towards 
autologous Epstein–Barr virus (EBV) infected B cells (auto-
BLCL). In one MS patient, the T-cell response towards 
autoBLCL in paired intra-lesional TCL was dominated by 
TCRVβ2+CD8+ T cells, which were localized in the paren-
chyma of the respective tissues expressing a polarized TCR 
and CD8 expression suggesting immunological synapse for-
mation in situ. Collectively, the data suggest the involvement 
of effector memory cytotoxic T cells recognizing antigens 
expressed by autoBLCL, but not the assayed human cMSAg, 
in WML of MS patients.
Keywords Multiple sclerosis · Pathogenesis ·  
CD8 T cells · Autoantigens · Epstein–Barr virus
Introduction
Multiple sclerosis (MS) is a chronic debilitating dis-
ease characterized by inflammation of the central nerv-
ous system (CNS), leading to demyelination and axon 
damage. The cause and pathogenic pathways involved 
remain enigmatic. MS is considered the result of a local 
Abstract T cells are considered pivotal in the pathology 
of multiple sclerosis (MS), but their function and antigen 
specificity are unknown. To unravel the role of T cells in 
MS pathology, we performed a comprehensive analysis on T 
cells recovered from paired blood, cerebrospinal fluid (CSF), 
normal-appearing white matter (NAWM) and white matter 
lesions (WML) from 27 MS patients with advanced disease 
shortly after death. The differentiation status of T cells in 
these compartments was determined by ex vivo flow cytom-
etry and immunohistochemistry. T-cell reactivity in short-
term T-cell lines (TCL), generated by non-specific stimula-
tion of T cells recovered from the same compartments, was 
determined by intracellular cytokine flow cytometry. Central 
memory T cells predominated in CSF and effector memory 
T cells were enriched in NAWM and WML. WML-derived 
 CD8+ T cells represent chronically activated T cells express-
ing a cytotoxic effector phenotype (CD95L and granzyme 
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inflammatory response in genetically susceptible indi-
viduals initiated by environmental factors [12, 17].
MS immunopathology has been widely studied in 
experimental autoimmune encephalomyelitis (EAE) ani-
mal models. EAE is induced by immunization with candi-
date MS-associated CNS autoantigens (cMSAg) in adju-
vant and by adoptive transfer of cMSAg-specific  CD4+ 
T cells. These studies reinforced the idea that MS is an 
autoimmune disease mediated by cMSAg-specific  CD4+ 
Th1/Th17 cells [28]. Indeed,  CD4+ T-cell responses to 
the majority of EAE-inducing cMSAg have been identi-
fied in peripheral blood (PB) and occasionally CSF of MS 
patients [17, 18, 28]. However, their frequency in PB of 
MS patients was indifferent compared to controls, ques-
tioning their pathogenic potential [17, 19]. The additional 
role of  CD8+ T cells in MS and EAE immunopathology 
has only recently emerged [19, 28]. In MS patients,  CD8+ 
T cells outnumber  CD4+ T cells in active lesions and 
closely interact with oligodendrocytes and demyelinating 
axons [12, 19, 41].  CD8+ T cells infiltrates in active white 
matter lesions (WML) are oligoclonal and persist in CSF 
and peripheral blood [5, 48, 55]. Human cMSAg-specific 
 CD8+ T cells lyse human leukocyte antigen (HLA) class 
I-matched oligodendrocytes in vitro [26, 35, 57]. The 
cytotoxic effector mechanisms involve both the Fas/FasL 
and perforin/granzyme B (grB) pathways [11, 40, 50, 57].
Current data advocate Epstein–Barr virus (EBV) 
infection as risk factor in MS [33, 39]. The epidemio-
logical similarity of MS and EBV-induced infectious 
mononucleosis (IM), enhanced systemic B- and T-cell 
responses to EBV in MS patients compared to (disease) 
controls, and the putative presence of EBV-infected 
B cells in MS lesions are indicative [4, 43, 53]. Even 
though evidence for the presence of EBV in MS lesions 
remains incredulous, [45] EBV may evoke T-cell-medi-
ated MS immunopathology in different ways [8, 20]. 
Virus-specific T cells may recognize EBV-infected cells 
in the brain or alternatively cross-react with cMSAg 
[61]. Alternatively, IM-associated systemic immune acti-
vation may result in a cytokine environment that acti-
vates pathogenic T cells, including cMSAg-specific T 
cells, in an antigen-independent manner [33, 39].
The aims of this study were to characterize the differ-
entiation status and antigen specificity of T cells recov-
ered from paired white matter tissues containing WML, 
normal-appearing white matter (NAWM), CSF and PB 
from 27 patients with advanced MS.
Materials and methods
Clinical specimens
Heparinized PB (3–6 ml; n = 19), CSF (8–20 ml; 
n = 17), and macroscopically defined NAWM (n = 23) 
and WML (n = 29), were obtained from 27 MS patients 
(median age 59 years, range 35–95 years) at autopsy with 
a median post-mortem interval of 9.6 h (range 4.8–14 h) 
(Online Resource 1). All patients had advanced disease 
(median disease duration 25 years, range 10–54 years), 
expanded disability status scale >6 and the majority had 
primary or secondary progressive MS (22 of 25, 88%). 
Leading cause of death was legally granted euthanasia for 
11 of 27 (44%) patients. Additionally, 12 formalin-fixed 
and paraffin-embedded (FFPE) tissues of 10 diseased 
MS patients were collected (Online Resource 2). Clini-
cal specimens of deceased MS patients were collected 
by the Netherlands Brain Bank (NBB; Amsterdam, The 
Netherlands) and genital skin biopsies of six patients 
with herpes simplex virus type 2 (HSV-2) genital herpes 
(GH) were obtained by the department of Dermatology 
and Venereology (Erasmus MC, Rotterdam, The Nether-
lands). Written informed consent for brain autopsy and 
genital skin biopsies, use of clinical specimens and clini-
cal information for research purposes have been obtained 
in advance from all study participants. Study procedures 
were performed in compliance with Dutch legislation and 
institutional guidelines, approved by the respective local 
ethical committees for use of MS patient material (Pro-
ject Number 2009/148; VU University Medical Center, 
Amsterdam) and skin biopsies of GH patients (Project 
Number MEC 167.153/1998/15; Erasmus MC) per-
formed in accordance with the ethical standards as laid 
down in the 1964 Declaration of Helsinki and its later 
amendments or comparable ethical standards. During 
autopsy, WML was distinguished macroscopically from 
NAWM based on gray appearance and by being firm to 
touch. PB was used to generate EBV-transformed B-cell 
lines (BLCL) and for 2-digit HLA typing as described 
[60]. Part of white matter tissues (1–4 g) were snap-fro-
zen and stored at −80 °C for subsequent in situ analysis. 
Remaining tissue was dispersed to single cell suspen-
sions as described [60]. About one-tenth of the single cell 
suspension was snap-frozen for subsequent EBV-specific 
EBER1 transcript expression analysis and remaining cells 
were used for ex vivo flow cytometric analysis and to 
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generate short-term T-cell lines (TCL) as described [60]. 
In brief, CSF and lymphocyte-enriched brain tissue cell 
suspensions were stimulated with phytohemagglutinin-L 
(1 µg/ml; Roche, Branford, CT) for 10–14 days and sub-
sequently with an anti-CD3 monoclonal antibody (mAb) 
(clone OKT-3; Janssen-Cilag, Tilburg, The Netherlands) 
for 10–14 days in the presence of γ-irradiated (3000 rad) 
allogeneic PBMC and recombinant human interleukin 2 
(rIL-2; 50 IU/ml) and rIL-15 (25 ng/ml; both Miltenyi 
Biotec, Bergisch Gladbach, Germany) [43].
In situ analyses of brain tissues
To classify the WM tissues of MS patients, brain tissues 
were characterized by immunohistochemistry (IHC) as 
NAWM, diffuse white matter abnormalities (DWMA), 
active lesions (AL), mixed active/inactive lesions (mAIL) 
and inactive lesions (IL) as described in the recently updated 
classification system for MS brain lesions [29] (repre-
sentative stainings of defined WM tissues of MS patients 
are shown in Online Resource 3). In brief, consecutive 7- 
to 9-µm cryostat brain sections were air-dried, fixed with 
acetone and subsequently assayed for: (1) (de-)myelination 
by anti-myelin oligodendrocyte protein (MOG) (clone Z12; 
kindly provided by prof. Sandra Amor, VU Medical Center, 
Amsterdam); (2) immune activation using anti-HLA-DP/
DQ/DR mAb (CR3/43; Dako, Glostrup, Denmark); (3) 
presence of macrophages and microglia using anti-CD68 
(clone EMB11; Dako). Granzyme B expressing T cells 
were detected in consecutive 6-µm sections of FFPE mAIL 
tissue of four representative MS patients stained for CD3 
(clone F7.2.38), CD8 (C8/144B), grB (GrB-7, all Dako). 
Stainings were visualized by 3-amino-9-ethylcarbazole as 
described [60]. Intracellular localization of grB and cyto-
toxic potential of  CD8+ T cells was assessed in 8-µm FFPE 
sections by triple immunofluorescent stainings using mAb 
directed to CD8 (clone YTC182.20, AbD Serotec), grB and 
cleaved caspase 3 (cCASP3; clone G7481, Promega, Madi-
son, USA). The presence of tissue-resident T cells  (TRM) 
was assessed analogously by detecting CD8, CD69 (FN50, 
Biolegend) and CD103 (2G5.1, Thermo Fisher) expression 
in WML of MS patients and as control skin biopsies of GH 
patients.  CD8+ T cells expressing grB in the parenchyma 
and perivascular space of mAIL sections were counted in 
multiple z-stack scans acquired at 400× magnification. To 
determine the CNS cell types encountered by intra-lesional 
 CD8+ T cells, double-immunofluorescence stainings were 
performed on 8-μm FFPE sections of WML biopsies. CNS 
cell types were visualized using mAbs directed to neuron-
specific neurofilament heavy chain (NF-H, clone SMI-31, 
Biolegend), microglia-specific ionized calcium-binding 
adapter molecule 1 (Iba1; clone 019-19741, Wako, Osaka, 
Japan), oligodendrocyte-specific proteolipid protein (PLP; 
clone plpc1, AbD Serotec) and astrocyte-specific glial 
fibrillary acidic protein (GFAP; clone Z0334, Dako) com-
bined with an anti-CD8 mAb (C8/144B). Antibody binding 
was visualized by AF488-conjugated Rat IgG (A-11006), 
AF568-conjugated IgG1 (A-21124), AF488- or AF647-
conjugated IgG2a (A-21131 or A-21241) or AF647-con-
jugated rabbit IgG-specific (A-21246, all Invitrogen) anti-
bodies. To detect T-cell receptor beta chain 2 (TCRVβ2) 
expressing T cells in situ, 8-µm cryostat brain sections 
were stained with APC-conjugated CD8 (RPA-T8, BD), 
FITC-conjugated TCRVβ2 (MPB2D5; Beckman Coulter) 
and laminin (L9393; Sigma) mAb combined with AF594-
conjugated anti-rabbit IgG (R37119; Invitrogen). TCRVβ2 
staining was amplified using the FASER kit (Miltenyi Bio-
tec). For all fluorescent stainings, nuclei were stained with 
4′,6-diamidino-2-phenylindole (DAPI) to visualize nuclei 
and sections scanned using LSM700 confocal microscope 
and Zen 2010 software (Zeiss; Oberkochen, Germany). 
Appropriate (fluorochrome-) matched Ig isotype antibodies 
were used as negative controls for all stainings and stain-
ings scored by two independent observers.
Ex vivo T‑cell phenotyping
Paired PB-, CSF-, NAWM- and WML-derived cells were 
incubated with combinations of fluorochrome-conju-
gated mAb directed to following markers: CD3 (clone 
UCHT1), CD4 (SK3 or RPA-T4), CD8 (SK1 or RPA-T8), 
CD27 (M-T271), CD45 (TU116), CD56 (B159), CD137 
(4-1BB; all Becton Dickinson (BD), Franklin Lakes, NJ), 
CD57 (HCD57), CD95L (NOK-1), ICOS (C398.4A), PD1 
(EH12.2H7), TIM3 (F38-2E2; all Biolegends, San Diego, 
CA) and CD45RA (HI100; Pharmingen, San Diego, CA). 
Cells were measured on a Canto II flow cytometer (BD). 
Negative controls consisted of stainings with appropriate Ig 
isotype control antibodies. If a parent population contained 
<100 events, the gated cell population was omitted from 
further analysis.
Quantitative EBV transcript expression analysis
Snap-frozen brain tissue-derived single cell pellets were 
used for RNA isolation and cDNA synthesis as described 
[60]. EBV EBER1 transcript expression was quantified by 
real-time quantitative PCR (qPCR) using forward primer 
5′-TCATAGGGAGGAGACGTGTGT-3′, reverse primer 
5′-TGACCGAAGACGGCAGAAAG-3′ and probe 5’FAM-
AGACAACCACAGACACCGTGGTGACCA-3′MGB 
(all Eurogentec; Liege, Belgium). RNA isolated from 
water and BLCL served as negative and positive controls 
in each run, respectively. For each sample β actin tran-
scripts (Hs01060665_g1, Applied Biosystems) were used 
as positive control for RNA isolation and cDNA synthesis. 
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Sensitivity of the EBER1-specific qPCR was determined 
as 1–10 BLCL per  106 PBMC (data not shown). An ABI 
prism 7500 and Taqman Universal Master Mix (both 
Applied Biosystems; Nieuwerkerk, The Netherlands) were 
used for all qPCR reactions as described [60].
Functional T‑cell assays
T-cell reactivity towards EBV-infected B cells in CSF-, 
NAWM- and WML-TCL was determined by incubation 
with autologous EBV-transformed B-cell lines (auto-
BLCL) as antigen presenting cell (APC) as described 
previously [43]. The frequency of B cells in BLCL lines 
(n = 5) undergoing spontaneous lytic cycle infection was 
determined by flow cytometric analysis of EBV glyco-
protein 350 expression (clone OT.1C-2, kindly provided 
by prof. J.M. Middeldorp, VU Medical Center, Amster-
dam, The Netherlands). An allogeneic BLCL (BLCL-
GR; HLA-A*01;03, -B*07;27, -C*02;07, -DRB1*13;15, 
-DQB1*06;06), carrying the major MS-associated HLA 
class I and II risk alleles (HLA-A*03, -DRB1*15 and 
-DRB1*13) [49], was transduced to express the seven 
following human cMSAg constitutively: (1) oligoden-
drocyte-specific proteins [myelin-associated glycopro-
tein (MAG), myelin basic protein isoform 1 (MBP1) 
and myelin oligodendrocyte glycoprotein (MOG)]; (2) 
neuron-specific proteins [contactin-2 (CNTN2) and 
155-kDa isoform of neurofascin (NFASC)] and (3) glia-
specific proteins [inwards rectifying potassium channel 
(KIR4.1) and S100 calcium-binding protein B (S100B)] 
[42]. Stable cMSAg-expressing BLCL-GR lines, vali-
dated by flow cytometry using cMSAg-specific mAb, 
were used as allogeneic APC to detect cMSAg-specific 
 CD4+ and  CD8+ T cells simultaneously in TCL of 
HLA-matched MS patients (Online Resource 1) [42]. To 
validate this BLCL platform, we also transduced BLCL-
GR to express measles virus fusion protein (MVF) and 
assayed their APC function by incubation with MVF-
specific  CD4+ (4-F99) and  CD8+ (2-F40) T-cell clones 
(TCC) as described previously [43]. Stimulated T cells 
were stained with fluorochrome-conjugated mAb to 
human CD3 (SP34-2), CD4 (SK3), CD8α (RPA-T8) and 
for viability (violet live/dead stain; Invitrogen). Subse-
quently, cells were fixed, permeabilized and stained for 
intracellular IFNγ (B27) and CD137 (4-1BB, all BD) 
and finally measured on a Canto II flow cytometer. Com-
bined intracellular IFNγ and CD137, two independent 
T-cell activation markers induced upon antigenic stimu-
lation, was set as criterion to identify antigen-specific T 
cells [10, 43]. TCL stimulated with phorbol myristate-
acetate (PMA; 50 ng/ml) and ionomycin (Iono; 500 ng/
ml; both Sigma), or mock-stimulated TCL, were used as 
positive and negative control, respectively. Netto reac-
tivity of  CD4+ and  CD8+ T cells towards cMSAg-trans-
duced BLCL-GR was calculated by subtracting T-cell 
reactivity to cMSAg-transduced BLCL-GR with mock-
transduced BLCL-GR. Threshold for positive cMSAg 
T-cell reactivity was calculated as previously reported 
[42]. Experiments were performed on at least two inde-
pendent occasions.
T‑cell receptor repertoire analysis
The clonality of NAWM- and WML-derived TCL was 
determined using a set of fluorochrome-conjugated mAb 
to 24 different human TCRVβ chains covering approxi-
mately 70% of the known human TCRVβ repertoire 
(IOTest Beta Mark mAb kit; Beckman Coulter, Marseille, 
France) combined with mAb to CD3, CD4 and CD8. 
TCRVβ usage of autoBLCL-specific T cells in WML-TCL 
was identified by CD3, CD4, CD8 and TCRVβ combined 
with intracellular IFNγ staining and flow cytometry. T-cell 
clonality was also determined by the TCR gamma (TCRγ) 
gene rearrangement Assay 2.0 (Invivoscribe, San Diego, 
CA) performed in duplo on DNA isolated from FACS-
sorted viable  CD8+ T cells of paired brain tissue-derived 
TCL of eight MS patients, and as control PBMC and two 
monoclonal human T-cell leukemic cell lines (MOL3 and 
KL 1985-001), according to manufacturers’ instructions 
(Invivoscribe).
Fig. 1  CD8+ T cells in normal-appearing and diseased white mat-
ter tissues of MS patients preferentially express an effector memory 
phenotype. a, b Parenchymal T cells are selectively detected in active 
MS lesions. 10-µm cryostat sections of paired (a) normal-appearing 
white matter (NAWM) and (b) white matter lesion (WML) of two 
representative patients of five MS patients analyzed. CD3 express-
ing cells (T cells) were stained with 3-amino-9-ethylcarbazole (red 
color) and counterstained with hematoxylin (blue color). Whereas 
perivascular T cells were detected in both NAWM and WML, paren-
chymal T cells were exclusively detected in active WML of MS 
patients. c Percentages of  CD4+ and  CD8+ T cells, and  CD4+/CD8+ 
T-cell ratio, are shown for paired PB (open circles), CSF (closed cir-
cles) and histologically defined as NAWM (open squares) and WML 
(filled squares). Lymphocytes were isolated from paired peripheral 
blood (PB), cerebrospinal fluid (CSF), NAWM and WML (lesion) 
from patients with advanced MS (n = 17) and subjected to multi-
plex flow cytometry. Gating procedure of  CD4+ and  CD8+ T cells 
is shown in Online Resource 3. d  CD8+ T cells were subdivided in 
naïve  (CD27+CD45RA+), central memory (CM;  CD27+CD45RA−), 
effector memory (EM;  CD27−CD45RA−) and terminally differenti-
ated effector memory (EMRA;  CD27−CD45RA+) T cells. Gating 
procedure is shown for representative paired PB and WML-derived 
 CD8+ T cells. e The frequency of naïve, CM, EM and EMRA  CD8+ 
T cells is shown for paired PB, CSF and white matter brain tissues 
that were immunohistologically classified as NAWM, diffuse white 
matter abnormalities (DWMA), active lesions (AL), mixed active/
inactive lesions (mIAL), inactive lesion (IL) or unconfirmed white 
matter tissues (UWM) (see Online Resource 3 for criteria applied for 
MS WM classification). Horizontal lines represent the mean frequen-
cies. Wilcoxon matched pairs test was used to calculate significance
◂
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Data analysis and statistics
Flow cytometry data were analyzed with FlowJo (Tree Star 
Inc., Ashland, OR) software. Paired data were assessed 
using Wilcoxon-signed rank test. Significance of variation 
in cMSAg- and autoBLCL-specific T-cell reactivity was 
determined by ANOVA for  CD4+ and  CD8+ T cells sepa-
rately. Unpaired t-test was used to determine significance 
Fig. 2  CD8+ T cells in white 
matter lesions of MS patients 
preferentially express CD69, but 
not CD103. a, b Representative 
triple immunofluorescent stain-
ings on 8-μm cryosections of 
a skin biopsies from six genital 
herpes patients and b immu-
nohistochemically classified 
white matter lesions (WML) of 
six MS patients. Tissues were 
stained for CD8 (green color), 
CD69 (white color) and CD103 
(red color) using specific 
monoclonal antibodies (mAbs) 
and isotype specific fluoro-
chrome-conjugated second-
ary antibodies. Sections were 
counterstained with 4′,6-diami-
dino-2-phenylindole (DAPI; 
blue color) and analyzed using 
a Zeiss LSM-700 confocal laser 
microscopy and ZEN software. 
Skin biopsies of genital herpes 
patients were stained as positive 
control to validate staining 
strategy by confirming localiza-
tion tissue-resident  CD8+
 
T cells based on differential 
CD69 and CD103 staining: 
 CD8+CD69+CD103− (a; inset 
1) and  CD8+CD69+CD103+ T 
cells (a; inset 2).  b In WML of 
MS patients, perivascular (top 
panels) and parenchymal  CD8+ 
T cells (bottom panels) were 
incidentally  CD69−CD103− T 
cells (b; insets 3 and 5) and 
predominantly  CD69+CD103− 
T cells (b; insets 4 and 6). Size 
bar is indicated in top-right 
image
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Fig. 3  CD8+ T cells in white matter lesions of MS patients are 
chronically activated T cells expressing a cytotoxic effector T-cell 
phenotype. Flow cytometric analysis of cytotoxic molecule CD95L 
and co-stimulatory receptor CD137 (a, b), co-inhibitory receptors 
TIM3 and PD1 (c, d) and co-stimulatory molecule ICOS and senes-
cence marker CD57 (e, f) expression on  CD8+ T cells in paired 
peripheral blood (PB, open circles), cerebrospinal fluid (CSF, closed 
circles) and brain tissues histologically defined as normal-appear-
ing white matter (NAWM, open squares) and white matter lesions 
(WML, filled squares) classified as diffuse white matter abnormalities 
(DWMA), active lesions (AL), mixed active/inactive lesions (mIAL) 
and inactive lesions (IL) of 17 MS patients (see Online Resource 3 
for criteria applied for MS WM classification). Lymphocyte gat-
ing was performed as described in the legend of Online Resource 4. 
Gating strategies and percentages of marker positive  CD8+ T cells 
in paired anatomic compartments are shown. If a parent population 
contained <100 events, daughter populations were omitted in further 
analysis. Horizontal lines indicate the mean. Wilcoxon matched pairs 
test was used to calculate significance
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Fig. 4  CD8+ T cells in white 
matter lesions of MS patients 
express granzyme B. a Rep-
resentative stainings on 6-µm 
sections of a formalin-fixed 
and paraffin-embedded (FFPE) 
mixed active/inactive white 
matter lesion (mAIL) of one 
of four MS patients analyzed. 
CD3 (top panel), CD8 (middle 
panel) and granzyme B (grB) 
expressing cells (bottom panel) 
were stained with 3-amino-
9-ethylcarbazole (red color) and 
counterstained with hema-
toxylin (blue color). Abundant 
punctate expression of grB was 
detected in perivascular (insets 
I, III and V) and parenchymal 
(insets II, IV and VI)  CD8+ T 
cells. Granzyme B polarization 
was observed in both perivas-
cular and parenchymal  CD8+ 
T cells (insets V and VI). b 
Representative maximum inten-
sity projections of z-stack laser 
confocal microscopy images 
of immunofluorescent triple 
stainings for grB (green color), 
CD8 (red color) and the early 
apoptotic cell marker “cleaved 
caspase-3” (cCASP3; white 
color). Stained sections were 
counterstained with DAPI (blue 
color). Representative stainings 
of three mAIL are shown of 12 
immunohistochemically clas-
sified WML tissues of 10 MS 
patients analyzed. Punctated 
(inset 1) and polarized grB 
expression by  CD8+ T cells 
(insets 3 and 5), as well as 
grB-negative  CD8+ T cells are 
shown (insets 2, 4 and 6). Co-
localization of grB and cCASP3 
is observed in a cell adjacent to 
a  CD8+ T-cell with polarized 
grB suggesting grB-mediated 
killing of the respective target 
cell (inset 5). Dotted line repre-
sents the glia limitans separat-
ing the perivascular space and 
parenchyma. c The grB-express-
ing  CD8+ T cells were counted 
in the perivascular space and 
parenchyma of mAIL of four 
MS patients analyzed. Wilcoxon 
matched pairs test was used to 
calculate significance
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of autoBLCL T-cell reactivity. All statistical analyses were 
performed using Graphpad Prism 5 software (Graph Pad 
Inc., La Jolla, CA).
Results
Macroscopically defined NAWM of MS patients 
with advanced disease contain diffuse white matter 
abnormalities
To characterize the role of T cells in MS, we collected 
paired PB, CSF, NAWM and WML specimens from 27 
deceased patients with advanced MS (Online Resource 
1). The presence and classification of the WM tissues 
sampled was determined by IHC on representative snap-
frozen sections of surplus NAWM and WML sections 
(Online Resource 3) [29]; provided adequate size of 
brain tissues was available. All macroscopically defined 
lesions were confirmed as WML and all contained demy-
elinated areas classified as AL, mAIL or IL [29]. Notably, 
9 of 20 (45%) macroscopically defined NAWM tissues 
presented as DWMA consisting of increased numbers 
of macrophage/microglia and high HLA class II expres-
sion (Online Resource 1). These DWMA represent peri-
plaque abnormalities, Wallerian degeneration or pre-
lesional changes [29]. The spatial distribution of T cells 
was determined on paired NAWM and WML tissues from 
five MS patients. In both NAWM and active WML, T 
cells were mainly detected in the Virchow–Robin space 
(Fig. 1a). However, parenchyma-infiltrating T cells were 
selectively observed in WML suggesting that these T 
cells are not part of immune surveillance, but rather 
involved in the local inflammatory response [41, 56].
Effector memory  CD8+ T cells are the main T‑cell 
subset in NAWM and WML of MS patients
To determine the phenotype and differentiation status of 
T cells in MS patients ex vivo, paired PB, CSF, and lym-
phocyte-enriched NAWM- and WML-derived single cell 
suspensions of 17 MS patients were subjected to multiplex 
flow cytometric analysis. T cells were selected by lympho-
cyte,  CD45high and CD3 gating, and finally sub-classified 
as  CD3+CD4high and  CD3+CD8high T cells based on PB-
derived T cells. In contrast to PB and CSF, brain tissue-
derived  CD3+ cells frequently expressed low levels of 
CD4 or CD8, and on occasion were devoid of CD4 and 
CD8 expression (Online Resource 4). As these different 
T-cell subtypes are difficult to differentiate by flow cytom-
etry and no consensus exists in literature on their origin, 
we omitted them from further analysis and only focused 
on T cells expressing high levels of CD4 or CD8. The lat-
ter uniform gating strategy was chosen to compare the 
activation and differentiation status of the same  CD4+ 
and  CD8+ T cells between multiple anatomic locations of 
the same individual. In both NAWM and WML,  CD8+ T 
cells dominated as shown by the significantly lower  CD4+/
CD8+ T-cell ratio in NAWM and WML compared to PB 
and CSF (Fig. 1c).
Next, the differentiation status of T cells was com-
pared between compartments based on differential surface 
expression of CD45RA and CD27 (Fig. 1c) [10]. Naive 
 (TNA;  CD27+CD45RA+)  CD8+ T cells were readily identi-
fied in PB, less frequently in CSF and rarely in NAWM and 
WML (Fig. 1d). Central memory  (TCM;  CD27+CD45RA−) 
 CD8+ T cells were the dominant phenotype in CSF. Effec-
tor memory  (TEM;  CD27−CD45RA−)  CD8+ T cells pre-
dominated in both NAWM and WML, with frequencies 
twofold higher compared to PB and CSF. Finally, termi-
nally differentiated memory  (TEMRA;  CD27−CD45RA+) 
T-cell frequencies were equivalent in PB, NAWM and 
WML, but lower in CSF. No significant differences in 
 CD4+/CD8+ T-cell ratio and  CD8+ T-cell differentiation 
status were observed between different WM types. Low 
numbers of  CD4+ T cells in most WML and NAWM speci-
mens precluded conclusive definition of their differentia-
tion status (data not shown). In conclusion,  CD8+  TEM cells 
are enriched in both NAWM and WML of the MS patients 
analyzed.
The expression of CD69 and CD103, two proteins 
described to enhance long-term retention of T cells within 
peripheral tissues also referred as  TRM cells [51], was deter-
mined on  CD8+ T cells in WML cryosections of six MS 
patients by triple immunofluorescence staining. We first 
validated our staining protocol by analyzing skin biop-
sies of 6 HSV-2 GH patients. In agreement with a previ-
ous study, the majority of human genital skin  CD8+  TRM 
expressed CD69 and about 20% of these cells co-expressed 
CD103 (Fig. 2a) [46, 51]. In contrast, both perivascular 
and parenchymal  CD8+ T cells in WML of MS patients 
exclusively expressed the  CD8+CD69+CD103− phenotype 
(Fig. 2b). These data contrast previous studies on mouse 
CNS- and human glioma-derived  CD8+ T cells showing 
that about half of  CD8+CD69+  TRM cells in CNS tissue 
co-express CD103 [27]. Because CD69 is also expressed 
by T cells early after TCR and cytokine activation [9], 
and since CD103 is debated as reliable  TRM marker [34], 
the  CD8+CD69+CD103− T cells detected in WML of the 
MS patients analyzed may denote genuine  CD8+  TRM cells, 
represent activated T cells or a mixture thereof [10, 27, 34, 
51].
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Phenotype of  CD8+ T cells in white matter lesions 
of MS patients implicate a local antigen‑specific 
cytotoxic T‑cell function
To determine the effector function and activation status of 
 CD8+ T cells ex vivo between different compartments of 
MS patients, expression of the death signal and co-stimula-
tory receptor FasL (CD95L) and the early activation marker 
CD137 were determined by multiplex flow cytometry on 
 CD8+ T cells (Fig. 3a). Expression of both CD95L and 
CD137 is induced on antigen-stimulated  CD8+ T cells and 
interaction of FasL with its receptor Fas may lead to target 
Acta Neuropathol 
1 3
cell lysis [10]. Compared to PB, significantly more  CD8+ T 
cells in WML were positive for CD95L and CD137, which 
was predominantly observed in DWMA (Fig. 3b).
In addition to the Fas/FasL-pathway, T-cell cytotoxic-
ity involves exocytosis of granules containing perforin and 
granzymes [38]. Previous studies showed lowered [56] or 
absent [30] intrathecal expression of perforin and grB by 
 CD8+ T cells in non-inflammatory CNS conditions, sug-
gesting a functionally repressed phenotype of CNS surveil-
ling T cells. Contrastingly,  grB+CD8+  TEM cells appeared 
enriched in CSF of MS patients [22]. To address this issue, 
consecutive sections of mAIL WML from four MS patients 
were stained for CD3, CD8 and grB (Fig. 4a). Whereas the 
majority of  CD8+ T cells showed abundant whilst punc-
tated grB expression, a fraction of  CD8+ T cells showed 
a more polarized grB expression pattern in both perivascu-
lar and parenchymal  CD8+ T cells (Fig. 4a). GrB distribu-
tion and cytotoxic potential of  CD8+ T cells was confirmed 
using z-stack confocal laser microscopy on 12 WML biop-
sies of 10 additional MS patients assayed by triple immu-
nofluorescence staining for CD8, grB and the early apop-
totic marker “cleaved caspase 3” (cCASP3). Occasionally 
adjacent cells expressed cCASP3 suggesting  CD8+ T-cell-
mediated cytotoxicity in situ (Fig. 4b). Parenchymal  CD8+ 
T cells were most frequently identified in mAIL (data not 
shown). The frequency of grB-expressing  CD8+ T cells in 
the parenchyma tended to be higher compared to the paired 
perivascular regions in mAIL (Fig. 4c). Collectively, the 
data indicate that  CD8+ T cells in WML of MS patients 
analyzed express a cytotoxic phenotype indicative for T 
cells recognizing their cognate antigen in situ [38].
CD8+ T cells in white matter lesions of MS patients 
are chronically activated T cells expressing a cytotoxic 
effector T‑cell phenotype
The repertoire of co-stimulatory and co-inhibitory recep-
tors determines the fate of T cells after antigenic challenge 
[10, 58]. Chronic antigenic stimulation leads to upregula-
tion of co-inhibitory receptors that negatively affect their 
proliferative potential, effector function and survival [10]. 
In CNS, co-signaling via transmembrane immunoglobu-
lin mucin 3 (TIM3) and programmed cell death type 1 
(PD1) are important immunoregulatory mechanisms [25]. 
Hence, the frequency of  CD8+ T cells expressing TIM3 
and PD1 ex vivo was compared between different compart-
ments by multiplex flow cytometry (Fig. 3c, d). Compared 
to PB, significantly more  CD8+ T cells in both CSF and 
MS lesions expressed TIM3 and PD1. In WML, this was 
largely attributed to  CD8+ T cells in DWMA. Chronic 
T-cell stimulation may ultimately result in an apoptosis-
resistant and senescent phenotype, characterized by human 
natural killer-1 receptor expression (CD57). This pheno-
type is potentially reverted by specific cytokines (e.g., IL-2 
and IL-15) resulting in upregulated expression of the induc-
ible co-stimulator (ICOS) molecule on T cells [58]. No sig-
nificant difference was observed in ex vivo CD57 expres-
sion by  CD8+ T cells between different compartments, 
arguing against senescent  CD8+ T cells in MS (Fig. 3e, f). 
Frequencies of  ICOS+CD8+ T cells were significantly ele-
vated in WML compared to PB and CSF, but were similar 
between NAWM and the different types of WML. Collec-
tively, the data demonstrate that  CD8+ T cells in WML of 
MS patients exhibit characteristics of chronically activated 
T cells.
To identify the brain cell types that interact with  CD8+ 
T cells, double-immunofluorescence stainings on WML 
tissue sections of 12 FFPE tissues of 10 MS patients 
were performed (Online Resource 2). Hereto, anti-CD8 
mAb was combined with antibodies directed to specific 
proteins expressed by human astrocytes (GFAP), micro-
glia (Iba1), oligodendrocytes (PLP) and neurons (NF-H) 
(Fig. 5). Perivascular  CD8+ T cells interacted preferen-
tially with astrocytes and microglia. Parenchymal  CD8+ 
T cells interacted with astrocytes, microglia, oligoden-
drocytes in fully myelinated and partially demyelinated 
areas. Moreover, they interacted with neurons in areas 
with and without prominent axonal swelling, indicative 
of neuronal stress or axonal damage due to demyelination 
[6]. Hence,  CD8+ T cells in WML of the MS patients ana-
lyzed showed no preferential interaction with a specific 
brain cell type (Fig. 5).
Fig. 5  CD8+ T cells interact with all major brain-resident cell types 
in white matter lesions of MS patients. Representative double-immu-
nofluorescence stainings on 8-μm sections of 12 formalin-fixed 
paraffin-embedded white matter lesion (WML) tissues from 10 MS 
patients are shown for a glial fibrillary acidic protein (GFAP: marker 
for astrocytes); b ionized calcium-binding adapter molecule 1 (Iba1: 
marker for microglia); c proteolipid protein (PLP: marker for oligo-
dendrocytes) and d neurofilament heavy chain (NF-H: marker for 
neurons; all green color) combined with CD8 (red color), counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI; blue color) and 
finally analyzed using a Zeiss LSM-700 confocal laser microscopy 
and ZEN software. Perivascular  CD8+ T cells interact with astrocytes 
(a left and middle panel) and microglia (b left and middle panel). 
Parenchymal  CD8+ T cells also interact with astrocytes (a right 
panel), microglia (b right panel) and oligodendrocytes (c) in fully 
myelinated (left panel) and partially demyelinated areas (middle and 
right panels). Parenchymal  CD8+ T cells also interact with neurons 
(d) in areas without (left panel), with moderate (middle panel) and 
with prominent axonal swelling (right panel). The latter is indicative 
of axonal damage. Insets show specific interactions between  CD8+ T 
cells and the major brain-resident cells analyzed for. Scale bar is indi-
cated (a, top left panel)
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Correlation of TCR repertoire between TCL generated 
from distinct lesions of the same MS patient
The markers expressed by  CD8+ T cells in WML suggest 
antigen-driven activation and potentially retention of spe-
cific TCC in affected tissue of MS patients (Figs. 3, 4). 
Given the low T-cell numbers in the clinical specimens 
obtained, T-cell clonality was assayed on short-term TCL 
generated by non-specific stimulation of T cells recovered 
from paired CSF, NAWM and WML specimens. TCRVβ 
chain usage of  CD4+ and  CD8+ T cells was determined 
by flow cytometry on paired NAWM- and WML-TCL 
(n = 4 patients) and paired WML-TCL (n = 6 patients) 
(Online Resource 5). Most TCL showed oligoclonal 
TCRVβ repertoires, but no specific TCRVβ predominated 
among patients. Whereas the TCRVβ repertoire of paired 
NAWM- and WML-TCL did not match, a significant cor-
relation was observed for  CD4+ and particularly  CD8+ 
T cells in paired WML-TCL of two and four of six MS 
patients, respectively (Online Resource 5). The shared 
TCRVβ chain usage implicates enrichment of specific TCC 
in distinct WML of the same MS patient. To address this 
issue in more detail, we assayed the composition of the 
TCR repertoire of  CD8+ T cells in paired NAWM/WML- 
(n = 3) and WML/WML-TCL (n = 5) by performing 
TCRγ-rearrangement spectratyping on sorted  CD8+ T cells 
(Online Resource 6) [13]. The TCRG locus is rearranged 
early during T-cell development in both TCR-αβ and -γδ 
lineage precursors and is considered the prototypic TCR 
locus for the detection of T-cell clonality in clinical speci-
mens [13]. Typical polyclonal Gaussian curves signify-
ing polyclonality, or one or two peaks illustrative for the 
rearrangement of the TCRG locus on one or both chromo-
somes, were detected when human PBMC or monoclonal 
T-cell leukemic cell lines (MOL3 and KL 1985-001) were 
assayed, respectively (Online Resource 6) [13]. TCRG 
GeneScan analyses demonstrated a reproducible, mark-
edly restricted pattern of TCRG rearrangements by  CD8+ 
T cells in the brain-derived TCL analyzed. These data con-
firm that the oligoclonal  CD8+ T-cell populations in TCL 
generated from paired NAWM and WML of the same 
MS patient were clonally distinct (patients #2, #4 and #8; 
Online Resource 6), whereas  CD8+ T cells in paired WML-
TCL of multiple MS patients showed a strong clonal over-
lap (patients #5, #6, #7 and #9; Online Resource 6). These 
data suggest that the paired WML sampled contained iden-
tical  CD8+ TCC potentially involved in the disease process.
No substantial T‑cell responses towards human 
candidate MS‑associated autoantigens in T‑cell lines 
generated from cerebrospinal fluid and white matter 
of MS patients
Previous studies, both on EAE and MS patients, support a 
key role of pathogenic T cells directed to various cMSAg 
including glia- (KIR4.1, S100B), oligodendrocyte- (MAG, 
MBP, MOG) and neuron-specific proteins (CNTN2 and 
NFASC) [17–19]. However, autoreactive T cells are also 
a physiological component of the healthy immune sys-
tem making disease association difficult [17–19]. Among 
the various genetic predictors of MS development, three 
specific HLA-I and -II alleles have been identified: HLA-
A*0301, -DRB1*1501 and -DRB*1301 [49]. Their asso-
ciation with MS may involve presentation of specific 
cMSAg-derived peptides that trigger pathogenic T-cell 
responses [44].
To test this hypothesis,  CD4+ and  CD8+ T-cell reac-
tivity towards these seven human cMSAg was deter-
mined for TCL of MS patients (n = 14) carrying the 
Fig. 6  T-cell lines generated from paired cerebrospinal fluid and 
white matter brain tissue of MS patients show no substantial T-cell 
reactivity towards candidate human MS-associated autoantigens. 
Short-term T-cell lines (TCL) were generated by non-specific stimu-
lation of T cells recovered from paired cerebrospinal fluid (CSF) and 
white matter brain tissues from 14 MS patients, which were immuno-
histologically classified as normal-appearing white matter (NAWM), 
diffuse white matter abnormalities (DWMA), active lesions (AL), 
mixed active/inactive lesions (mAIL), inactive lesions (IL) or unde-
fined white matter tissue (UWM) (see Online Resource 3 for criteria 
applied for MS WM classification). An HLA-matched Epstein–Barr 
virus-transformed B-cell line (i.e., BLCL-GR) was used to assay 
T-cell reactivity towards candidate human MS-associated autoan-
tigens (cMSAg). a Antigen-specific T cells were enumerated by 
determining co-expression of intracellular interferon gamma (IFNγ) 
and CD137 using multiplex flow cytometry. Gated  CD8+ T cells 
from mAIL-derived TCL of MS patient #27 (see Online Resource 
1) is representatively shown.  CD8+ T cells alone (top panel), stimu-
lated with untransduced BLCL-GR (middle panel) or with phorbol 
myristate-acetate (PMA) and ionomycin (Iono) are shown. b The 
frequency of IFNγ and CD137 co-expressing  CD4+ (left panel) 
and  CD8+ T cells (right panels) that were cultured alone (top pan-
els) or co-cultured with untransduced BLCL-GR (middle panels) are 
shown. The bottom panel shows the frequency of IFNγ-expressing 
 CD4+ (left panel) and  CD8+ T cells (right panel) after stimulation 
with a cocktail of T-cell mitogens (i.e., PMA and Iono). c BLCL-GR 
were nucleofected with human candidate MS autoantigens (cMSAg) 
expression vectors encoding human contactin-2 (CNTN2), inwards 
rectifying potassium channel (KIR4.1), myelin-associated glyco-
protein (MAG), myelin basic protein isoform 1 (MBP1), myelin oli-
godendrocyte glycoprotein (MOG), neurofascin (NFASC) or S100 
calcium-binding protein B (S100B). TCL were co-cultured with the 
respective cMSAg-expressing BLCL-GR and the phenotype and 
frequency of cMSAg-specific T cells determined by flow cytometry. 
The netto frequency of cMSAg-specific T cells, corrected for reac-
tivity towards untransduced BLCL-GR, is shown as the percentage 
IFNγ+CD137+  CD4+ (left panel) and  CD8+ T cells (right panel). 
Symbols represent the individual MS patients analyzed (n = 14; spec-
ified at the bottom of the figure). The majority of TCL were assayed 
at least two times, of which vertical lines represent the mean and 
standard deviation. Horizontal dashed lines depict the cut-off for pos-
itive calls for  CD4+ and  CD8+ T cells, allowing a 0.1% false discov-
ery. Significance of variation in cMSAg-specific T-cell reactivity was 
determined by ANOVA for  CD4+ and  CD8+ T cells separately
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three MS-associated HLA risk alleles (Online Resource 
1). Hereto, an allogeneic BLCL (BLCL-GR), matched 
for these three HLA alleles, was transduced and selected 
in vitro to express the individual cMSAg, and measles 
virus fusion protein as control T-cell antigen, constitu-
tively at high level (data not shown) [42]. Because no 
human cMSAg-specific T-cell clone or lines were avail-
able, we used MVF-transduced BLCL-GR as APC to 
validate the applicability of our expression system to 
process and present endogenously expressed antigens by 
both HLA-I and II. As shown previously, both the MVF-
specific  CD4+ (4-F99) and  CD8+ TCC (2-F40) recog-
nized MVF-transduced GR-BLCL efficiently (data not 
shown) [42]. Next, human cMSAg-specific T-cell reactiv-
ity was determined by multiplex flow cytometry on CSF-, 
NAWM- and WML-TCL of HLA-matched MS patients 
using the cMSAg-transduced BLCL-GR as antigen pre-
senting cells (Fig. 6). Whereas TCL only and TCL co-
cultured with untransduced BLCL-GR showed limited 
T-cell responses, TCL stimulated with a cocktail of the 
T-cell mitogens PMA and Iono showed a uniformly high 
expression of the T-cell activation marker IFNγ demon-
strating that the T cells in the TCL were immunocompe-
tent and not exhausted (Fig. 6a, b).
The BLCL-GR-reactive  CD4+ (mean ± SD 2.1% ± 2.4) 
and  CD8+ (1.3 ± 2.0%) T-cell responses of the CSF- and 
brain tissue-derived TCL were low and the inter-assay vari-
ation was 1.69% for  CD4+ T cells and 1.44% for  CD8+ T 
cells in independent replicate experiments. Consequently, 
the threshold for positive calls was 5.6% for  CD4+ T cells 
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and 4.4% for  CD8+ T cells allowing a one-tailed 0.1% 
false discovery rate [42]. Marginal cMSAg-specific T-cell 
responses were detected in only 4 of 207 (1.9%) cMSAg/
TCL-combinations, including two CSF-TCL (Fig. 6c). 
Overall, the limited cMSAg-specific T-cell reactivity in 
paired CSF-, NAWM- and WML-TCL argues against their 
involvement in the perpetuation of disease in the 14 MS 
patients analyzed.
T cells recovered from white matter lesions of MS 
patients recognize autologous Epstein–Barr 
virus‑infected B cells
Epstein–Barr virus infection is a major environmental risk 
factor to develop MS in genetically predisposed individu-
als [33, 49]. Recent data argue for a role of EBV-specific 
T cells in MS pathology [2, 32, 43], but proof of their 
presence in brain tissues of MS patients is lacking. This 
prompted us to investigate T-cell responses towards auto-
BLCL in paired CSF-, NAWM- and WML-TCL. Con-
cordant with earlier studies, about 5% of autoBLCL cells 
expressed the late lytic viral antigen glycoprotein 350, 
demonstrating that these cells have spontaneously entered 
the lytic cycle and most likely expressed the whole EBV 
proteome (Online Resource 7). Accordingly, autoBLCL 
were considered appropriate APC to analyze EBV-specific 
T-cell reactivity [1, 43]. Due to limited cell numbers and 
viability, autoBLCL could only be generated for nine MS 
patients. In contrast to NAWM- and DWMA-TCL, sub-
stantial T-cell responses towards autoBLCL, predomi-
nantly  CD8+ T cells, were detected in multiple mAIL- and 
the sole AL-TCL analyzed. This response was most pro-
nounced among IAL-TCL: five of seven IAL-TCL assayed 
had brisk T-cell responses towards autoBLCL-specific 
(Fig. 7a). Notably, these strong  CD8+ T-cell responses cor-
related between paired TCL generated from distinct mAIL 
of the same patient: MS patients #6 and #9 (Fig. 7a). The 
data implicate enrichment of autoBLCL-reactive  CD8+ T 
cells in AL and mAIL of MS patients that are potentially 
involved in the disease process [57].
These autoBLCL-reactive T cells are potentially 
enriched in brain tissue due to local stimulation by EBV 
proteins [53]. Hence, we determined the presence of the 
EBV transcript EBER1, which is highly expressed during 
both latent and lytic EBV infection [59], in surplus brain 
tissue from which the respective NAWM- and WML-TCL 
were generated. No EBER1 RNA was detected implicating 
that productive EBV infection or the presence of latently 
EBV-infected B cells in the brain tissues sampled is highly 
unlikely (data not shown).
Clonally expanded autologous BLCL reactive  CD8+ 
T cells are located in brain parenchyma and form 
immune synapses
The combined data on congruent TCR clonality, selec-
tive TCRVβ expression by  CD8+ T-cell showing reactiv-
ity towards autoBLCL in paired intra-lesional TCL sug-
gest local enrichment of the same  CD8+ TCC. Among 
the high autoBLCL T-cell responders, sufficient T-cell 
quantities were only available for the mAIL-TCLs of MS 
patient #6 for follow-up studies. TCRVβ analysis revealed 
that TCRVβ2+ T cells dominated the oligoclonal  CD8+ 
T-cell response towards autoBLCL in the paired intra-
lesional TCL of MS patient #6: mAIL-TCL#1 (32%) and 
#2 (89%) (Fig. 7b). Furthermore, the autoBLCL-reactive 
 CD4+ T-cell response in mAIL-TCL#2 was restricted to 
TCRVβ22 (99%) expressing T cells. Next, we localized 
TCRVβ2+CD8+ T cells, as proxy for the dominant auto-
BLCL-reactive  CD8+ TCC, by IHC in the respective WML 
Fig. 7  White matter lesion-derived  CD8+ T cells recognize autolo-
gous Epstein–Barr virus-transformed B cells and localize in the 
parenchyma to form immune synapses. a Short-term T-cell lines 
(TCL) were generated by non-specific stimulation of T-cell recov-
ered from paired cerebrospinal fluid (CSF) and white matter brain 
tissues from nine MS patients, which were immunohistologically 
classified defined as normal-appearing white matter (NAWM), dif-
fuse white matter abnormalities (DWMA), active lesions (AL), mixed 
active/inactive lesions (mAIL) and inactive lesions (IL) (see Online 
Resource 3 for criteria applied for MS WM classification). The TCL 
were incubated with autologous Epstein–Barr virus-transformed B 
cell lines (autoBLCL). Next, the phenotype and frequency of auto-
BLCL-specific T cells was determined by co-expression of intracel-
lular interferon gamma (IFNγ) and CD137 using multiplex flow 
cytometry. The frequency of autoBLCL-reactive T cells is shown 
as the percentage of IFNγ+CD137+  CD4+ (left panel) and  CD8+ T 
cells (right panel). Symbols represent individual donors (n = 9; speci-
fied in the legend) and vertical lines represent the mean and standard 
deviation of at least two independent experiments per TCL. Signifi-
cance of variation in autoBLCL T-cell reactivity was determined by 
ANOVA for  CD4+ and  CD8+ T cells separately. b TCL generated 
from two anatomically distinct mAIL of MS patient #6 (see Online 
Resource 1) were cultured with autoBLCL to assay the T-cell recep-
tor variable β chain (TCRVβ) usage of the reactive T cells, deter-
mined by intracellular interferon gamma (IFNγ) expression, using 
multiplex flow cytometry. The frequency of  CD4+ (left x-axis) and 
 CD8+ T cells (right x-axis) of specific TCRVβ families (y-axis) are 
depicted (gray bars lesion #1, black bars lesion #2). The frequency of 
autoBLCL-reactive  CD4+ T cells and  CD8+ T cells of each TCRVβ 
family is shown (stacked green bars IFNγ+ T cells). Results shown 
are representative for two independent experiments. “Und.” refers to 
T cells expressing a TCRVβ chain not covered by the TCRVβ-family-
specific monoclonal antibody panel used. c Triple immunofluores-
cence staining for TCRVβ2 (green color), laminin (orange color) and 
CD8 (red color) in surplus WML tissue sections (8 µm) containing 
WML #1 and #2, from which the corresponding TCLs shown in panel 
“A” were generated. Nuclei were stained with DAPI (blue color). 
TCRVβ2+  CD8+ T cells reside in the perivascular cuff (open arrow-
head) and the parenchyma (closed arrowhead) of both distinct WML 
of the same patient. The majority of parenchymal T cells show polari-
zation of both CD8 and TCRVβ2 (encircled cells in top-right insets). 
Images of representative stainings are shown
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tissues. The TCRVβ2+CD8+ T cells were detected in the 
Virchow–Robin space and parenchyma in both mAIL of 
patient #6 (Fig. 7c). Notably, the majority of parenchymal 
TCRVβ2+CD8+ T cells showed polarization of both TCR 
and CD8, indicative for immune synapse formation and 
confirmed by Z-stack analysis (Online Resource 8). Col-
lectively, the data suggest the involvement of  CD8+ T cells 
recognizing antigens expressed by autoBLCL, and poten-
tially the same TCC, in the inflammatory process in two 
distinct mAIL of the same MS patient.
Discussion
The current study provides novel insights into the pheno-
typic and functional characteristics of the T-cell response in 
CSF and (non-)affected brain tissue of MS patients. Three 
main findings are reported. First, T cells in MS lesions 
are predominantly  CD8+  TEM cells expressing a cytotoxic 
effector phenotype indicative for local antigenic stimula-
tion. Second, T cells cultured from WML in four of nine 
MS patients recognize autoBLCL. This reactivity was pro-
found in TCL generated from AL and mAIL. Third, no 
substantial T-cell reactivity was observed towards seven 
human cMSAg in CSF- and brain tissue-derived TCL of 
MS patients expressing the major MS-associated HLA risk 
alleles HLA-A*03, -DRB1*15 and -DRB1*13.
During the past decade, the focus on the role of  CD4+ 
T cells in MS pathology has shifted towards  CD8+ T 
cells; the most abundant T-cell subset identified in active 
WML of MS patients [12, 19]. The antigen specificity 
(e.g., autoantigens and/or EBV proteins) and the poten-
tial role of intra-lesional  CD8+ T cells (cytotoxic or reg-
ulatory) in MS pathology is still a matter of debate [3, 
22, 41, 54]. The infrastructure of the Netherlands Brain 
Bank and the commitment of MS patients to donate their 
tissues after death for research purposes, offered us the 
unique opportunity to compare the phenotype, function 
and reactivity of T cells between paired PB, CSF, NAWM 
and WML of 27 MS patients. Notably, the study design 
enabled comparison of T cells between compartments 
intra-individually, hereby limiting influence of inter-
patient immune differences that are potentially unrelated 
to MS. A limitation of our study was, however, that all 
MS patients included had a long progressive disease 
course. Nevertheless, in situ characterization of the mac-
roscopically defined NAWM and WML tissues obtained 
clearly demonstrated the presence of lesions cover-
ing the complete spectrum of MS disease activity rang-
ing from DWMA to IL [29]. Markedly, about half of the 
macroscopically defined NAWM contained DWMA that 
represent periplaque abnormalities, Wallerian degenera-
tion or pre-lesional abnormalities [29]. The relative high 
frequency of these type of diffuse abnormalities out-
side of focal MS lesions in end-stage MS patients raises 
doubt if all DWMA will progress to active lesions, which 
necessitates identification of specific markers that identi-
fies the origin and fate of DWMA in time.
Concordant with previous studies, T cells were located 
in perivascular spaces of both NAWM and WML, whereas 
parenchymal T cells were restricted to WML of MS 
patients [41, 47]. The ex vivo distribution of  CD8+  TNA, 
 TCM,  TEM and  TEMRA cells in NAWM, WML and CSF of 
MS patients resembled data on WM and CSF under normal 
CNS conditions [16, 56]. However, compared to paired PB, 
 CD8+ T cells in WML of the MS patients analyzed showed 
significantly increased expression of markers indicative for 
antigen-induced cytotoxicity (CD59L and grB) and activa-
tion (CD69, grB and CD137). The increased expression 
of the co-inhibitory (TIM3 and PD1) and co-stimulatory 
receptors (ICOS), whilst not accompanied with increased 
CD57 expression, suggests that the  CD8+ T-cell underwent 
chronic activation in situ while retaining their proliferative 
potential. In comparison, CSF-derived  CD8+ T cells had 
increased expression of both co-inhibitory markers, which 
refutes active involvement in CNS pathology [47]. Con-
trary to normal CNS conditions [56],  CD8+ T cells in MS 
lesions expressed grB, suggesting that they encountered 
their cognate antigen locally and are potentially cytotoxic 
T cells [30, 38]. Indeed, occasionally  CD8+ T cells with 
polarized grB expression were localized adjacent to cells 
showing signs of early apoptosis. However, detailed in situ 
analysis could not demonstrate a specific brain-resident cell 
type preferentially targeted by  CD8+ T cells in the WML 
analyzed. Furthermore, the majority of WML-derived 
 CD8+ T cells expressed CD69, which in the absence of 
CD103 co-expression may reflect their activated state or 
indicate a specific subset of  TRM cells [10, 27]. Overall, 
the activated and cytotoxic effector memory phenotype of 
 CD8+ T cells in WML, along with overlapping TCRVβ 
repertoires between paired WML-TCL of the same patient, 
implicate clonally expanded T cells recognizing their cog-
nate antigen locally. These  CD8+ T cells are potentially 
involvement in the deleterious CNS inflammation that con-
tributes to MS pathogenesis [38].
To decipher the cognate antigen driving T-cell activa-
tion in MS lesions, we analyzed T-cell reactivity in short-
term TCL generated from different compartments of the 
same patient using autologous or alternatively an alloge-
neic HLA-matched BLCL stably transduced with seven 
human cMSAg (i.e., CNTN2, KIR4.1, MAG, MBP1, 
MOG, NFASC and S100B) [42, 43]. The expression of 
three well-described MS-associated HLA-I and -II risk 
alleles (i.e., HLA-A*0301, -DRB1*1501 and -DRB*1301; 
[50]) by the allogeneic BLCL-GR facilitated simultaneous 
detection of  CD4+ and  CD8+ T-cell responses in TCL of 
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HLA-matched MS patients towards endogenously syn-
thesized and processed human cMSAg [42]. Notably, no 
substantial cMSAg-specific T-cell reactivity was detected 
in TCL generated from CSF, NAWM and WML of 14 MS 
patients. The data concur with recent studies on CSF-TCL 
of patients with early MS describing negligible intrathecal 
cMSAg-specific T-cell reactivity [42, 62], but are in con-
trast to other studies showing brisk systemic and occasional 
local T-cell reactivity towards distinct cMSAg-specific syn-
thetic peptides in MS patients [9, 14, 17, 18, 37]. These dis-
crepancies may be methodological or related to the timing 
of tissue sampled during the course of disease. Most studies 
assayed cMSAg-specific T-cell reactivity using autologous 
PBMC as APC pulsed with high concentrations synthetic 
peptides (10–250 µM) or recombinant (animal) cMSAg. 
However, disease-irrelevant T cells expressing low-avidity 
TCR are potentially activated by these super-physiological 
peptide concentrations [7]. Also, due to species differences, 
amino acid composition and conformation of the synthetic 
peptides used may differ from natural T-cell epitopes [15]. 
The BLCL/cMSAg platform used in this study offered a 
more physiological approach to detect cMSAg-specific 
 CD4+ and  CD8+ T-cell responses as compared to more 
conventional APC platforms used previously [42]. Our ina-
bility to detect cMSAg-specific T-cell reactivity may be due 
to the inclusion of specimens from patients with advanced 
MS disease in which the disease-initiating cMSAg-specific 
T-cell response that potentially sparked of disease is not 
actively involved in perpetuating MS pathology. Alterna-
tively, cMSAg-derived peptides were presented by other 
HLA alleles not shared with the allogenic BLCL-GR. 
Nevertheless, the inability to detect intra-lesional cMSAg-
specific T-cell responses in end-stage MS patients, as well 
as in CSF of patients with clinical isolated syndrome and 
early MS [42], does not support the long-held hypothesis 
that the cMSAg assayed here are prominent targets of local 
pathogenic T-cell responses in MS patients.
Contrastingly, brisk T-cell reactivity (mainly  CD8+ 
T cells) was detected towards autoBLCL, preferen-
tially among TCL generated from AL and mAIL, but 
not DWMA and IL, suggesting their involvement in 
lesion activity. On occasion, these strong  CD8+ T-cell 
responses were identified in TCL generated from ana-
tomically separated WML of the same MS patient, sug-
gesting involvement of the same TCC in both lesions. 
Indeed, even though observed in a single MS patient and 
not confirmed at the TCR level, the autoBLCL-reactive 
 CD8+ T-cell response in the paired mAIL-TCL of this 
particular MS patient was dominated by TCRVβ2+  CD8+ 
T cells. These T cells were detected in the parenchyma 
of the respective WML tissues of the same patient with 
polarized TCR and CD8 expression suggesting immuno-
logical synapse formation in situ. Recently, we and others 
have shown intrathecal  CD8+ T-cell reactivity to EBV 
antigens in patients with early MS [24, 31, 43]. Because 
no EBV transcripts could be detected in the correspond-
ing WML assayed here, the autoBLCL-specific  CD8+ 
T-cell responses identified are most likely not involved to 
combat intracerebral EBV infection as suggested by oth-
ers [2, 53]. The cognate antigen could be an EBV pro-
tein, an autoantigen induced or selectively processed in 
EBV-infected B cells or an EBV/cMSAg-cross-reactive 
autoantigen [21, 23, 32, 36, 52, 61]. A limitation of our 
APC platform, using BLCL as APC, is that it withholds 
clear distinction between these options. Unfortunately, 
autologous activated B cells were not available to deter-
mine if the T-cell reactivity towards autoBLCL truly tar-
geted EBV antigens. Furthermore, due to limited numbers 
of T cells available from the autoBLCL-reactive TCL, in-
depth cognate EBV antigen discovery as described previ-
ously was also not possible [43].
In conclusion, the data presented suggest that cyto-
toxic  CD8+  TEM cells directed to autoBLCL, but not to 
the seven human cMSAg assayed in combination with 
three major MS-associated HLA risk alleles, are poten-
tially involved in the immunopathology of white matter 
lesions of the MS patients analyzed. Follow-up studies on 
WML-derived T cells are warranted to identify the cog-
nate virus and/or host antigen recognized by this poten-
tial deleterious autoBLCL-reactive T-cell response in MS 
patients.
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